This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Pilot Study of the Efficacy and Safety of Q8003 in Patients Who Have Undergone Total Knee Arthroplasty or Total Hip Arthroplasty

This study has been completed.
Information provided by (Responsible Party):
QRxPharma Inc. Identifier:
First received: January 6, 2009
Last updated: May 15, 2012
Last verified: May 2012
This is a Phase 2 3-arm, open label pilot study of the safety and efficacy of Q8003 in patients who have undergone primary unilateral total knee arthroplasty or total hip arthroplasty.

Condition Intervention Phase
Postoperative Pain Drug: Q8003 (morphine sulfate and oxycodone hydrochloride) Drug: Low dose Q8003 (morphine sulfate and oxycodone hydrochloride) Drug: Percocet (oxycodone and acetaminophen) Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: An Open-Label Pilot Study of the Analgesic Efficacy and Safety Of Q8003 and of the Conversion From IV Morphine PCA Analgesia to Q8003 or to Percocet® in Patients Who Have Undergone Primary Unilateral Total Knee Arthroplasty or Total Hip Arthroplasty

Resource links provided by NLM:

Further study details as provided by QRxPharma Inc.:

Primary Outcome Measures:
  • Difference in pain intensity scores from baseline [ Time Frame: 48 hours ]

Secondary Outcome Measures:
  • Safety: adverse events [ Time Frame: Throughout the 48 hour period ]

Enrollment: 44
Study Start Date: February 2009
Study Completion Date: July 2009
Primary Completion Date: July 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Q8003, flexible ascending dose
Drug: Q8003 (morphine sulfate and oxycodone hydrochloride)
IR Capsules, ascending flexible dose, every 4 to 6 hours
Experimental: 2
Low dose Q8003
Drug: Low dose Q8003 (morphine sulfate and oxycodone hydrochloride)
One 3mg/2mg or 6mg/4mg IR Capsule every 4 to 6 hours
Active Comparator: 3
Percocet (oxycodone and acetaminophen)
Drug: Percocet (oxycodone and acetaminophen)
One or two 5mg/325 mg tablets every 4 to 6 hours

Detailed Description:

This Phase 2 study is a 3 arm, open-label pilot study to evaluate:

  • the analgesic efficacy of a flexible ascending regimen of Q8003 compared to a low dose regimen of Q8003 (3 mg/2 mg and potentially up to 6 mg/ 4mg) and to 1-2 Percocet® 5 mg/325 mg tablets. Study drug will be administered every 4-6 hours over a 48-hour Treatment Period to inpatients with moderate to severe postoperative pain who have undergone primary unilateral total knee arthroplasty or total hip arthroplasty.
  • for the flexible ascending regimen of Q8003 treatment group, to evaluate the adequacy of the algorithm for conversion of IV PCA morphine to oral morphine equivalent doses of Q8003.
  • the safety of the flexible ascending regimen of Q8003 administered over a 48-hour Treatment Period.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male of female, at least 18 years of age at time of enrollment.
  • If female, be at least one year post-menopausal, surgically sterile or practicing effective contraception, be non-lactating, and if of child-bearing potential, have a negative urine pregnancy test result.
  • Have a body mass index (BMI) of 38 kg/m2 or less.
  • Have undergone a primary unilateral total knee arthroplasty or total hip arthroplasty performed under standardized general, spinal or epidural anesthesia.
  • Have developed moderate to severe pain (a score of 2 or more on the 4 point Likert scale or at least 4 on the 11 point NPRS scale within 6 hours of discontinuing PCA on the morning after surgery).

Exclusion Criteria:

  • In the opinion of the Investigator, has a history of pulmonary, cardiovascular (including uncontrolled hypertension), neurologic, endocrine, hepatic, gastrointestinal, or kidney disease or therapy that, in the opinion of the Investigator, would jeopardize the patient's well being by participation in this study or is mentally or emotionally unsuitable to participate, or unable/unwilling to comply with the study assessments.
  • Used opiates continuously (including tramadol) for more than ten days in the past year.
  • Hypersensitivity or poor tolerance to ibuprofen or short term opioids.
  • Currently receiving any medications that are not at a stable dose (the same dose for > 2 months prior to date of surgery).
  • Was dosed with another investigational drug within 30 days prior to the Screening Visit or has previously received treatment with Q8003.
  • Current therapy with central nervous system depressant medications that might increase the risks of treatment with opioids (other than those used with surgical anesthesia).
  • Current evidence of alcohol abuse (regularly drinks more than 4 units of alcohol per day; 1 unit = ½ pint of beer, 1 glass of wine, or 1 ounce of spirit).
  • History of abusing licit or illicit drug substances within five (5) years of study entry.
  • Has taken drugs known to interact with morphine or oxycodone metabolism, including, but not limited to, phenothiazines, monoamine oxidase inhibitors (MAOI), amphetamines, and muscle relaxants within the 4 weeks prior to the date of surgery.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00818493

United States, Alabama
West Alabama Research, Inc.
Birmingham, Alabama, United States, 35209
United States, Arizona
Arizona Research Center
Phoenix, Arizona, United States, 85023
United States, Michigan
William Beaumont Hospital
Royal Oak, Michigan, United States, 48073
United States, Texas
Research Concepts, Ltd.
Houston, Texas, United States, 77024
Sponsors and Collaborators
QRxPharma Inc.
Study Director: Patricia T. Richards, MD, Ph.D. QRxPharma Inc.
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: QRxPharma Inc. Identifier: NCT00818493     History of Changes
Other Study ID Numbers: Q8003-020
Study First Received: January 6, 2009
Last Updated: May 15, 2012

Keywords provided by QRxPharma Inc.:
total knee arthroplasty
total hip arthroplasty

Additional relevant MeSH terms:
Pain, Postoperative
Neurologic Manifestations
Nervous System Diseases
Postoperative Complications
Pathologic Processes
Signs and Symptoms
Acetaminophen, hydrocodone drug combination
Analgesics, Opioid
Central Nervous System Depressants
Physiological Effects of Drugs
Sensory System Agents
Peripheral Nervous System Agents
Analgesics, Non-Narcotic
Anti-Inflammatory Agents, Non-Steroidal
Anti-Inflammatory Agents
Antirheumatic Agents processed this record on August 16, 2017